Research Sample bioBank
Small Cell Lung Cancer (SCLC) Clinical Research Samples
Discovery Life Sciences provides the highest quality Small Cell Lung Cancer (SCLC) Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Small Cell Lung Cancer (SCLC) Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
|Product ID||Sample||Origin||Matrix||Vial (ml)||Quantity||Price||Age||Gender||Ethnicity||Storage Temp||Sample Date||Test 1||Test Data 1||Sample Detail 1||Test 2||Product|
|Additional Information 1||Additional Data 1||Additional Information 2||Additional Data 2||Additional Information 3||Additional Data 3||Additional Detail 3||Additional Information 4||Additional Data 4||Additional Information 5||Additional Data 5||Additional Information 6||Additional Data 6||Additional Information 7||Additional Data 7||ICD10 codes|
|DLS17-049949-K2||Small Cell Lung Cancer (SCLC)||Russia||K2 EDTA Plasma||1.00||3.00||$150.00||66 Y||M||White||<-70C||23-Nov-17||Staging||IIIa; T4N1M0G4||28-Nov-17||Pre-Treatment||$150.00||Height | Weight||179 cm | 74 kg||Smoking History||Former 10-20 cigs/day for 30 years||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||4-Nov-17||Site of Primary Tumor||Right lung (lower lobe)||History of Benign Disease Prior to Cancer Diagnosis||No||Site of Metastasis||N/A||Current Medications||Bisoprolol, Amlodipine, Captopril||C34.32|
|DLS17-049952-K2||Small Cell Lung Cancer (SCLC)||Russia||K2 EDTA Plasma||1.00||3.00||$150.00||56 Y||M||White||<-70C||29-Nov-17||Staging||IIIa; T3N2M0G3||6-Dec-17||Pre-Treatment||$150.00||Height | Weight||169 cm | 72 kg||Smoking History||Former 15-20 cigs/day for 25 years||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||6-Nov-17||Site of Primary Tumor||Right bronchus (upper lobe)||History of Benign Disease Prior to Cancer Diagnosis||Chronic Bronchitis||Site of Metastasis||N/A||Current Medications||Omeprazole, Drotaverine||C34.11|
|DLS17-049955-K2||Small Cell Lung Cancer (SCLC)||Russia||K2 EDTA Plasma||1.00||3.00||$150.00||62 Y||M||White||<-70C||15-Nov-17||Staging||IIIa; T4N1M0G3||21-Nov-17||Pre-Treatment||$150.00||Height | Weight||178 cm | 84 kg||Smoking History||Former 15-20 cigs/day for 35 years||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||25-Oct-17||Site of Primary Tumor||Left lung (lower lobe)||History of Benign Disease Prior to Cancer Diagnosis||No||Site of Metastasis||N/A||Current Medications||Nifedipine, Captopril||C34.32|
|DLS17-049977-K2||Small Cell Lung Cancer (SCLC)||Russia||K2 EDTA Plasma||1.00||3.00||$150.00||58 Y||M||Asian||<-70C||26-Dec-17||Staging||IIIa; T3N2M0G3||4-Jan-18||Pre-Treatment||$150.00||Height | Weight||180 cm | 92 kg||Smoking History||Former 10-15 cigs/day for 20 years||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||3-Dec-17||Site of Primary Tumor||Right lung (middle lobe)||History of Benign Disease Prior to Cancer Diagnosis||Chronic Bronchitis||Site of Metastasis||N/A||Current Medications||None||C34.21|
|DLS17-049979-K2-HZ||Small Cell Lung Cancer (SCLC)||Russia||K2 EDTA Plasma||1.00||3.00||$150.00||62 Y||M||White||<-70C||12-Dec-17||Staging||IIb; T2N1M0G3||18-Dec-17||Pre-Treatment||$150.00||Height | Weight||184 cm | 81 kg||Smoking History||Former 15-20 cigs/day for 35 years||Date of Initial Primary Tumor Diagnosis||Bronchoscopy, Rx, CT||20-Nov-17||Site of Primary Tumor||Left lung (upper lobe)||History of Benign Disease Prior to Cancer Diagnosis||Chronic Bronchitis||Site of Metastasis||N/A||Current Medications||Hydrochlorothiazide, Amlodipine, Fosinopril||C34.12|
|DLS0068139-S||Small Cell Lung Cancer (SCLC)||USA||Serum||1.00||9.00||$150.00||60 Y||F||U/A||<-70C||27-Nov-18||Staging||IV||12-Oct-18||$150.00||Height | Weight||168cm | 82.1kg||Smoking History||Previous, 25-pack-years||Date of Initial Primary Tumor Diagnosis||3/23/2018||Site of Primary Tumor||Prostate||History of Benign Disease prior to Cancer Diagnosis||Diabetes type I||Site of Metastasis||Brain, bilateral adrenal glands, mediastinum, right hilum||Current Medications||Aspirin, ativan, medical marijuana, mirtazapine, novolin, oxycodone, prochlorperazine|
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.